Effectiveness of subcutaneous monoclonal antibody treatment in emergency department outpatients with COVID-19.

ABSTRACT:

Objectives

To evaluate whether subcutaneous neutralizing monoclonal antibody (mAb) treatment given in the emergency department (ED) setting was associated with reduced hospitalizations, mortality, and severity of disease when compared to nontreatment among mAb-eligible patients with coronavirus disease 2019 (COVID-19).

Methods

This retrospective observational cohort study of ED patients utilized a propensity score-matched analysis to compare patients who received subcutaneous casirivimab and imdevimab mAb to nontreated COVID-19 control patients in November-December 2021. The primary outcome was all-cause hospitalization within 28 days, and secondary outcomes were 90-day hospitalization, 28- and 90-day mortality, and ED length of stay (LOS).

Results

Of 1340 patients in

SUBMITTER: Wendel SK 

PROVIDER: S-EPMC10879902 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature